The present invention relates to therapeutic diazobicyclo pyridines and
their use in the treatment of arthritis, rheumatoid arthritis, psoriatic
arthritis or osteoarthritis, organ transplant, acute transplant or
heterograft and homograft rejection, ischemic and reperfusion injury,
transplantation tolerance induction, multiple sclerosis, inflammatory
bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs. host
diseases, T -cell mediated hypersensitivity diseases, contact
hypersensitivity, delayed-type hypersensitivity, gluten-sensitive
enteropathy, Type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's
thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Graves'
Disease, Addison's disease, autoimmune polyglandular disease, autoimmune
alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism,
Guillain-Barre syndrome, autoimmune diseases, glomerulonephritis, serum
sickness, uticaria, respiratory allergies, asthma, hayfever, allergic
rhinitis, skin allergies, scleracielma, mycosis fungoides, acute
inflammatory responses, acute respiratory distress syndrome,
dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema,
Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's
syndrome, atopic dermatitis, systemic schlerosis, morphea, Type II
diabetes and cancers where PKC theta or other PKC-family kinases are
activated, overexpressed or facilitate tumor growth or survival of tumor
cells, T cell leukemia, thymoma, T and B cell lymphoma, colon carcinoma,
breast carcinoma and lung carcinoma or provides resistance to
chemotherapeutic drugs.